Verastem, Inc. Common Stock VSTM
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-04T07:39:22.960Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:36:15.399019049Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-04T07:39:22.981601+00:00
Verastem, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 8.07 | 138.5% | 22.0% | |||
| 25Δ | 8.47 | 135.6% | 19.2% | |||
| 30Δ | 8.87 | 132.6% | 16.3% | |||
| 35Δ | 9.27 | 140.7% | 14.8% | |||
| 40Δ | 9.66 | 154.1% | 13.9% | |||
| 45Δ | ||||||
| 50Δ | 10.05 | 82.8% | 8.0% | |||
| 55Δ | 9.83 | 80.6% | 6.8% | |||
| 60Δ | 9.63 | 78.9% | 5.8% | |||
| 65Δ | 9.42 | 77.1% | 4.7% | |||
| 70Δ | 9.22 | 75.4% | 3.7% | 12.20 | 148.3% | 5.0% |
| 75Δ | 9.02 | 73.6% | 2.7% | 12.52 | 138.3% | 3.8% |
| 80Δ | 8.44 | 89.3% | 2.2% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.07
- IV
- 138.5%
- B/E move
- 22.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.47
- IV
- 135.6%
- B/E move
- 19.2%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.87
- IV
- 132.6%
- B/E move
- 16.3%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.27
- IV
- 140.7%
- B/E move
- 14.8%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.66
- IV
- 154.1%
- B/E move
- 13.9%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- 10.05
- IV
- 82.8%
- B/E move
- 8.0%
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 9.83
- IV
- 80.6%
- B/E move
- 6.8%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 9.63
- IV
- 78.9%
- B/E move
- 5.8%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 9.42
- IV
- 77.1%
- B/E move
- 4.7%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 9.22
- IV
- 75.4%
- B/E move
- 3.7%
- Pseudo strike
- 12.20
- IV
- 148.3%
- B/E move
- 5.0%
75Δ
- Pseudo strike
- 9.02
- IV
- 73.6%
- B/E move
- 2.7%
- Pseudo strike
- 12.52
- IV
- 138.3%
- B/E move
- 3.8%
80Δ
- Pseudo strike
- 8.44
- IV
- 89.3%
- B/E move
- 2.2%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 133.09% | |
| 116.87% | |
| 151.33% | |
| 137.61% | |
| 156.83% | |
| 142.94% | |
| 144.98% | |
| 144.44% | |
| 150.03% | |
| 125.86% |
Biotechnology
VYGR
Description unavailable
More →WHWK
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. The company is headquartered in…
More →WVE
Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes and produces new stereopure oligonucleotides through PRISM, a drug discovery and development…
More →XBIT
XBiotech Inc., a biopharmaceutical company, discovers, develops and markets True Human monoclonal antibodies for the treatment of various diseases. The company is headquartered in…
More →XENE
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders in Canada. The company…
More →XFOR
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for the treatment of back…
More →